奈立膦酸结构式
|
常用名 | 奈立膦酸 | 英文名 | Neridronate |
|---|---|---|---|---|
| CAS号 | 79778-41-9 | 分子量 | 277.149 | |
| 密度 | 1.7±0.1 g/cm3 | 沸点 | 600.1±65.0 °C at 760 mmHg | |
| 分子式 | C6H17NO7P2 | 熔点 | 245° | |
| MSDS | 中文版 美版 | 闪点 | 316.7±34.3 °C | |
| 符号 |
GHS07 |
信号词 | Warning |
奈立膦酸用途Neridronate 是一种氨基二膦酸盐,用于治疗成骨不全症 (OI) 和佩吉特骨病(PDB)。Neridronate 对其他骨骼疾病也有效,如骨质疏松症,骨痛退化症,恶性高钙血症和骨转移病变。 |
| 中文名 | 奈立膦酸 |
|---|---|
| 英文名 | neridronate sodium hydrate |
| 英文别名 | 更多 |
| 描述 | Neridronate 是一种氨基二膦酸盐,用于治疗成骨不全症 (OI) 和佩吉特骨病(PDB)。Neridronate 对其他骨骼疾病也有效,如骨质疏松症,骨痛退化症,恶性高钙血症和骨转移病变。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 密度 | 1.7±0.1 g/cm3 |
|---|---|
| 沸点 | 600.1±65.0 °C at 760 mmHg |
| 熔点 | 245° |
| 分子式 | C6H17NO7P2 |
| 分子量 | 277.149 |
| 闪点 | 316.7±34.3 °C |
| 精确质量 | 277.048035 |
| PSA | 180.93000 |
| LogP | -3.36 |
| 外观性状 | 白色固体 |
| 蒸汽压 | 0.0±3.9 mmHg at 25°C |
| 折射率 | 1.569 |
| 储存条件 | 2-8°C |
| 水溶解性 | H2O: 8 mg/mL, soluble |
| 符号 |
GHS07 |
|---|---|
| 信号词 | Warning |
| 危害声明 | H302 |
| 个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
| 危害码 (欧洲) | Xn: Harmful; |
| 风险声明 (欧洲) | R22 |
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 3 |
|
~89%
奈立膦酸 79778-41-9 |
| 文献：Alanne, Aino-Liisa; Ylisirnioe, Markku; Turhanen, Petri; Peraeniemi, Sirpa; Vepsaelaeinen, Jouko; Hyvoenen, Helena; Lahtinen, Manu; Kolehmainen, Erkki Molecules, 2012 , vol. 17, # 9 p. 10928 - 10945,18 |
|
~88%
奈立膦酸 79778-41-9 |
| 文献：Guenin, Erwann; Monteil, Maelle; Bouchemal, Nadia; Prange, Thierry; Lecouvey, Marc European Journal of Organic Chemistry, 2007 , # 20 p. 3380 - 3391 |
|
~%
奈立膦酸 79778-41-9 |
| 文献：US4407761 A1, ; |
|
~%
奈立膦酸 79778-41-9 |
| 文献：European Journal of Organic Chemistry, , # 20 p. 3380 - 3391 |
|
~%
奈立膦酸 79778-41-9 |
| 文献：European Journal of Organic Chemistry, , # 20 p. 3380 - 3391 |
| 奈立膦酸上游产品 4 | |
|---|---|
| 奈立膦酸下游产品 0 | |
|
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Eur. J. Pharm. Biopharm. 76(1) , 120-6, (2010) Recognition of bone mineral by bisphosphonates is crucial to their targeting, efficacy, therapeutic and diagnostic applications, and pharmacokinetics. In a search for rapid and simple NMR approaches t... |
|
|
Intramuscular neridronate in postmenopausal women with low bone mineral density.
Calcif. Tissue Int. 83(5) , 301-7, (2008) Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a ni... |
|
|
The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
Mini Rev. Med. Chem. 9(9) , 1052-63, (2009) Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil, a widely used immunosuppressant. Numerous studies have developed limited sampling strategies (LSSs) to predict MPA AUC in sol... |
| (6-Amino-1-hydroxy-1,1-hexanediyl)bis(phosphonic acid) |
| Neridronic |
| 6-amino-1-hydroxyhexane-1,1-diphosphonic acid |
| NERIXIA |
| 6-amino-1-hydroxy-1,1-hexylidenebisphosphonic acid |
| Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- |
| (6-amino-1-hydroxyhexylidene)bisphosphonate |
| 6-AMINO-1-HYDROXYHEXYLIDENE BISPHOSPHONIC ACID |
| 6-Amino-1-hydroxyhexylidene bisphosphonic acid,Neridronic acid,Nerixia |
| 6-amino-1-hydroxyhexane-1,1-diphosphonate |
| (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid |
| (6-Amino-1-hydroxyhexane-1,1-diyl)bis(phosphonic acid) |
| NERIDRONATE |
| Neridronic acid |
查看所有供应商和价格请点击：
![[6-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-1-hydroxy-1-phosphonohexyl]phosphonic acid结构式](https://www.chemsrc.com/caspic/048/948317-80-4.png)
